Project Grant R03MH140040

Award Date 5/1/25
Completion Date 4/30/27
Dollars Obligated $64K
Funding Federal Agency
Office of the Director
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Wisconsin, USA
Similar Awards
This $3,807,329 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to evaluate the effectiveness of a new intervention called Perinatal Understanding of Mindful Awareness for Sleep (PUMAS) in alleviating insomnia and preventing perinatal depression among pregnant women. The grant supports a large-scale randomized controlled trial (RCT) to test PUMAS, which combines behavioral sleep strategies with a...
This federal Project Grant award from the National Institute of Mental Health (CFDA 93.242 - Mental Health Research Grants) will fund a $393,212 research project to evaluate the efficacy of light therapy for reducing symptoms of obsessive-compulsive disorder (OCD) and examine changes in circadian rhythms as a potential mechanism. The 5-year project, awarded to The Washington University, will compare the effects of light therapy (n=20) versus placebo light therapy (n=20) on OCD symptom...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will fund the development and testing of a novel, emotion-focused group skills intervention for pregnant women with high emotion dysregulation. The $1,440,659 award to Duke University will support a two-phase study evaluating the impact of the new "Perinatal Dialectical Behavior Therapy Skills" (DBT-P) intervention. In the initial R61...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $945,397 to the Magee-Womens Research Institute and Foundation to adapt and evaluate a Collaborative Care Model (CCM) for providing integrated services to pregnant, postpartum, and parenting persons with opioid use disorder in low-resource obstetric settings. The key products and services to be delivered include: 1) adapting the CCM for rural and...
The University of Southern California (USC) was awarded a $1,330,840 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The grant, titled "MEGA-OCD: A Global Data-Driven Initiative to Discover Biosignatures of OCD," will fund a comprehensive, multi-year research project to investigate the neurobiological mechanisms underlying obsessive-compulsive disorder (OCD). The key objectives of the project are to: 1)...
This Project Grant award, valued at $239,250.00, was provided by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The funding will support an exploratory study investigating the role of the cholinergic system in the striatum of the brain and its potential involvement in obsessive-compulsive disorder (OCD). The research team, led by The Research Foundation For The State University Of New York (doing business as Stony Brook...
The National Institute of Mental Health (NIMH) awarded a $194,899 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the Icahn School of Medicine at Mount Sinai. The grant will fund a 5-year research project to investigate the neurocognitive mechanisms underlying compulsivity, a maladaptive behavior implicated in several psychiatric illnesses including obsessive-compulsive disorder (OCD). The project will use theory-driven computational modeling and trial-by-trial EEG analysis to...
This federal Project Grant award of $418,178 from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to provide mechanistic insights into the neurobiological mechanisms by which maternal sensitivity is compromised by postpartum depression. Specifically, the University of Massachusetts (UMass), through its Office of Grant & Contract Administration, will use intersectional viral...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...

TREATING OBSESSIVE-COMPULSIVE DISORDER DURING THE PERINATAL PERIOD - PROJECT SUMMARY/ABSTRACT THE PERINATAL PERIOD (PREGNANCY THROUGH ONE YEAR AFTER GIVING BIRTH) IS A TIME OF SIGNIFICANTLY ELEVATED RISK FOR BOTH THE ONSET AND EXACERBATION OF OBSESSIVE-COMPULSIVE DISORDER (OCD). OCD IS DEBILITATING AND COSTLY IN THE GENERAL POPULATION, BUT FOR PERINATAL WOMEN UNTREATED OCD CONFERS A HOST OF ADDITIONAL RISKS RANGING FROM SERIOUS DELIVERY COMPLICATIONS TO DELETERIOUS HEALTH OUTCOMES FOR BOTH THE PARENT AND INFANT. ALTHOUGH EFFECTIVE TREATMENTS FOR OCD EXIST, PARTICULARLY EXPOSURE AND RESPONSE PREVENTION (ERP) AND SEROTONIN REUPTAKE INHIBITORS (SRIS), THESE TREATMENTS HAVE NOT BEEN SYSTEMATICALLY STUDIED IN PERINATAL WOMEN IN PART BECAUSE PREGNANT INDIVIDUALS HAVE BEEN EXCLUDED FROM CLINICAL TRIALS DUE TO SAFETY CONCERNS. HOWEVER, PERINATAL WOMEN ARE PHYSIOLOGICALLY AND PSYCHOLOGICALLY DISTINCT FROM THE NON-PERINATAL SAMPLES ON WHOM ERP AND SRIS WERE EMPIRICALLY TESTED, AND THERE ARE MANY REASONS TO EXPECT THAT THE UNIQUE BIOLOGICAL AND PSYCHOSOCIAL CONTEXT OF PERINATAL WOMEN MIGHT UNDERMINE THE EFFICACY, TOLERABILITY, AND SAFETY OF FIRST-LINE OCD TREATMENTS. DESPITE THE DEARTH OF DATA AND THE NUMEROUS WAYS THAT PERINATAL-SPECIFIC CONSIDERATIONS ALTER THE TREATMENT CONTEXT, BOTH PREGNANT AND POSTPARTUM WOMEN SUFFERING FROM OCD ROUTINELY PRESENT TO REAL-WORLD CLINICAL SETTINGS SEEKING TREATMENT. TO RESPOND TO THIS MATERNAL AND FILIAL HEALTH CRISIS, RESEARCH IS URGENTLY NEEDED TO DETERMINE IF FIRST- LINE OCD TREATMENTS ARE EFFECTIVE, SAFE, AND TOLERABLE FOR PERINATAL WOMEN, AND HOW STANDARD CARE NEEDS TO BE TAILORED TO FIT THE PERINATAL CONTEXT. THIS PROPOSAL WILL LEVERAGE EXISTING PATIENT DATA COLLECTED AS PART OF STANDARD CARE AT A LARGE NATURALISTIC BEHAVIORAL HEALTHCARE SYSTEM TO ADDRESS THIS CRITICAL, YET DIFFICULT TO STUDY, CLINICAL ISSUE AND INFORM LARGER-SCALE RANDOMIZED-CONTROLLED TRIALS (RCTS) AIMED AT IMPROVING OUTCOMES FOR BIRTHING PARENTS AND THEIR FAMILIES. USING THE LARGEST PERINATAL OCD SAMPLE TO DATE (N = 94; 43 PREGNANT, 51 POSTPARTUM) AND AN EQUAL NUMBER OF PROPENSITY-SCORE-MATCHED NON-PERINATAL CONTROLS (TOTAL N = 188), THIS STUDY WILL IMPLEMENT A CASE-CONTROL DESIGN, RETROSPECTIVE CHART REVIEW, AND STATISTICAL MODELING TO EVALUATE THE FOLLOWING AIMS: 1) DETERMINE WHICH INTERVENTIONS ARE ADMINISTERED TO PERINATAL PATIENTS WITH OCD IN A NATURALISTIC SETTING; 2) EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF FIRST-LINE OCD TREATMENTS IN THE PERINATAL PERIOD; AND, 3) TO INFORM PERSONALIZING EFFORTS, EXPLORE HOW STANDARD TREATMENTS ARE ADAPTED FOR USE WITH PERINATAL PATIENTS AND WHETHER THESE MODIFICATIONS IMPROVE OUTCOMES. THIS PROPOSAL IS IN LINE WITH THE STRATEGIC RESEARCH PRIORITIES SET FORTH BY THE NIMH PERTAINING TO INVESTIGATING PERSONALIZED INTERVENTION STRATEGIES (OBJECTIVE 3.2.A), ESTABLISHING THE SAFETY AND EFFICACY OF INTERVENTIONS FOR WOMEN AT VARIOUS PHASES OF THE REPRODUCTIVE CYCLE (INTEREST AREA 3), AND THE NEED FOR ADDITIONAL RESEARCH ON WOMEN'S MENTAL HEALTH DURING THE PERINATAL PERIOD (NOT-MH-21-270). THIS STUDY WILL PROVIDE PRELIMINARY DATA ATTESTING TO THE SAFETY, TOLERABILITY, AND EFFICACY OF STANDARD AND MODIFIED OCD TREATMENTS IN THE PERINATAL PERIOD, THEREBY JUSTIFYING THE INCLUSION OF PREGNANT PARTICIPANTS IN A LARGER-SCALE RCT TO BE PROPOSED IN A SUBSEQUENT R61/R33 APPLICATION AND INFORMING THE NATURE OF THE TREATMENTS TO BE EVALUATED.

Posted 5/1/25, 12:00 AM